A bioengineered “supercharged” immune cell has been designed that is particularly efficient at targeting cancer cells.
At EPFL’s School of Engineering, Professor Li Tang’s Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research. In laboratory settings, this innovative CAR-T therapy has consistently eradicated cancerous tumors in mouse models. Separately, in on-going clinical trials, eleven patients seemed to achieve complete remission using this treatment, marking a success rate of 100% to date. Notably, evidence from the lab study, published in Nature Biotechnology, suggests the therapy’s long-term effectiveness, and indicates that its fabrication may be both quicker and more cost-effective than current methods.
